Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging

The results of recent studies of magnetic resonance imaging (MRI) combined with three-dimensional magnetic resonance spectroscopic imaging (3D-MRSI) demonstrate that the MRI/3D-MRSI exam is a unique method by which to noninvasively study the cellular metabolism and anatomy of the prostate. 3D-MRSI is emerging as the most specificity tool for non-invasive evaluation of the prostate cancer. The results of current MRI/3D-MRSI studies also provide evidence that the magnitude of metabolic changes in regions of cancer before therapy, as well as the extent of the time course of metabolic changes after therapy, may improve our understanding of cancer aggressiveness. Assessment of cancer spread outside the prostate can be significantly improved by combining MRI findings with estimates of metabolic abnormalities provided by 3D-MRSI. Clinically, combined MRI/3D-MRSI has already demonstrated a potential for improved diagnosis, staging, and treatment planning for patients with prostate cancer. This article reviewed the value of 3D-MRS imaging for the diagnosis, localization, staging, aggressiveness, and treatment planning of prostate cancer.

[1]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[2]  J. Lewin,et al.  Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation. , 1989, Radiology.

[3]  B. McNeil,et al.  Comparison of Magnetic Resonance Imaging and Ultrasonography in Staging Early Prostate Cancer. Results of a Multi-Institutional Cooperative Trial , 1991, Investigative Radiology.

[4]  J. Epstein.  Evaluation of Radical Prostatectomy Capsular Margins of Resection: The Significance of Margins Designated as Negative, Closely Approaching, and Positive , 1990, The American journal of surgical pathology.

[5]  P H Bland,et al.  Carcinoma of the prostate: MR images obtained with body coils do not accurately reflect tumor volume. , 1991, AJR. American journal of roentgenology.

[6]  R. Franklin,et al.  Concepts of citrate production and secretion by prostate 1. Metabolic relationships , 1991, The Prostate.

[7]  W. Heston.  Prostatic polyamines and polyamine targeting as a new approach to therapy of prostatic cancer. , 1991, Cancer surveys.

[8]  R E Lenkinski,et al.  Current role of MR imaging in the staging of adenocarcinoma of the prostate. , 1993, Radiology.

[9]  D. Mitchell,et al.  Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. , 1994, Radiology.

[10]  P. Carroll,et al.  Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal--pelvic phased-array coils. , 1994, Radiology.

[11]  C W Piccoli,et al.  Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. , 1994, Radiology.

[12]  A. Schned,et al.  Staging of prostate cancer with endorectal MR imaging: lessons from a learning curve. , 1995, Radiographics : a review publication of the Radiological Society of North America, Inc.

[13]  P. Carroll,et al.  Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. , 1995, Radiology.

[14]  J R Thornbury,et al.  Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. , 1996, AJR. American journal of roentgenology.

[15]  P. Carroll,et al.  Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. , 1996, Radiology.

[16]  P. Carroll,et al.  Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. , 1996, Urology.

[17]  Local Staging of Prostatic Carcinoma: Comparison of Transrectal Sonography and Endorectal MR Imaging , 1996 .

[18]  P. Carroll,et al.  Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. , 1996, Radiology.

[19]  W. Fair,et al.  Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. , 1997, The Journal of urology.

[20]  J. Kurhanewicz,et al.  Improved water and lipid suppression for 3D PRESS CSI using rf band selective inversion with gradient dephasing (basing) , 1997, Magnetic resonance in medicine.

[21]  S. Piantadosi,et al.  Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. , 1997, The American journal of surgical pathology.

[22]  S. Yao,et al.  Population-based study of long-term survival in patients with clinically localised prostate cancer , 1997, The Lancet.

[23]  R. Franklin,et al.  Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer , 1998, The Prostate.

[24]  C. Magi-Galluzzi,et al.  Apoptosis in Prostatic Adenocarcinoma following Complete Androgen Ablation , 1998, Urologia Internationalis.

[25]  J Kurhanewicz,et al.  Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. , 1998, Radiology.

[26]  J Kurhanewicz,et al.  Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. , 1999, Radiology.

[27]  R. Franklin,et al.  Inhibitory effect of zinc on human prostatic carcinoma cell growth , 1999, The Prostate.

[28]  P. Carroll,et al.  Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study. , 1999, Radiology.

[29]  D. Kuban,et al.  Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. , 1999, JAMA.

[30]  J Kurhanewicz,et al.  Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. , 2000, The Journal of urology.

[31]  J Kurhanewicz,et al.  The prostate: MR imaging and spectroscopy. Present and future. , 2000 .

[32]  R. Dunn,et al.  Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. , 2000, International journal of radiation oncology, biology, physics.

[33]  J Kurhanewicz,et al.  Time‐dependent effects of hormone‐deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging , 2001, Magnetic resonance in medicine.

[34]  E. Bergstralh,et al.  Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. , 2001, The Journal of urology.

[35]  A. Renshaw,et al.  Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. , 2002, Urology.

[36]  Juni Palmgren,et al.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2002, The New England journal of medicine.

[37]  Steven Piantadosi,et al.  Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. , 2003, The Journal of urology.

[38]  H. Hricak,et al.  Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings--initial observations. , 2004, Radiology.

[39]  W S Ng,et al.  Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. , 2004, The Journal of urology.

[40]  J. Kurhanewicz,et al.  Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. , 2004, Radiology.

[41]  V. Pansadoro,et al.  Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. , 2004, La Radiologia medica.

[42]  P. Carroll,et al.  Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. , 2004, Radiology.

[43]  F. Coakley,et al.  MR imaging and MR spectroscopic imaging of prostate cancer. , 2004, Magnetic resonance imaging clinics of North America.

[44]  Pierre I Karakiewicz,et al.  Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. , 2004, The Journal of urology.

[45]  J. Kurhanewicz,et al.  Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. , 2005, Radiology.

[46]  M. Zerbib,et al.  Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. , 2005, European urology.

[47]  M. Kattan,et al.  Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. , 2005, Radiology.

[48]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[49]  V. Pansadoro,et al.  Granulomatous prostatitis: A pitfall in endorectal MR imaging and 3D MR spectroscopic imaging , 2005 .

[50]  M. Kattan,et al.  Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. , 2006, Radiology.